NCT02296242View on ClinicalTrials.gov

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

BVD-523

Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

19104

Perelman Center for Advanced Medicine, Philadelphia

30322

Winship Cancer Institute of Emory University, Atlanta

77030

MD Anderson Cancer Center, Houston

90024

UCLA Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

BioMed Valley Discoveries, Inc

INDUSTRY

NCT02296242 - Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter